AMORPHICAL
Guy Slutsky is an experienced professional in the field of research and development, currently serving as VP of R&D and Clinical Trial Manager at AMORPHICAL from July 2023 to July 2024. Previously, Guy held multiple roles at Kadimastem Ltd. between January 2009 and January 2018, including Clinical Project Manager and Preclinical Study Manager focused on neurodegenerative diseases. Prior experience includes a research fellowship at the Weizmann Institute of Science and postdoctoral fellowships at both the University of Michigan and the Weizmann Institute. Guy earned a PhD in Molecular Genetics from the Weizmann Institute of Science and a Master of Science in Plant Molecular Biology from The Hebrew University of Jerusalem.
Previous companies
This person is not in any teams
This person is not in any offices
AMORPHICAL
Pioneer Israeli Biotechnology Company Established in 2004 developing novel solutions for number of major diseases. Amorphical has successfully developed a unique and stable form of Amorphous Calcium Carbonate (ACC), in nano-particle form (20-80 nm) employing proprietary process based on biomimicry-searching methods utilized by certain mammals. The unique features of ACC have demonstrated novel modes of actions that enable disease treatment in a number of conditions, as well as performance improvement of cells and organs. ACC has a much higher solubility than crystalline calcium carbonate (CCC) at mildly acidic conditions and neutral pH (100 times higher), compared to all similar calcium products in the market including Pfizer’s and GNC’s. ACC consists of nanometric primary particles in the range of 20 to 80 nanometers that are slightly agglomerated. ACC has a remarkable higher (double) calcium absorption, compared to other calcium supplement substances. ACC has remarkable higher calcium bioavailability and higher bioactivity, which is attributed to ACC’s capability to deliver the carbonate domains as a solid nanometric buffer.